Like any clinical trial, ECOG-ACRIN E2100 had limitations. The study's design did not allow for crossover between treatment arms, which could have influenced overall survival outcomes. Additionally, the higher incidence of adverse effects in the combination arm raised concerns about patient quality of life and management of side effects. Subsequent research and meta-analyses have provided further insights into the optimal use of bevacizumab in cancer treatment.
